| Symbol | BDSX |
|---|---|
| Name | BIODESIX INC |
| Sector | HEALTH CARE |
| Region | UNDEFINED |
| Industry | Services-Medical Laboratories |
| Address | 919 WEST DILLON ROAD, LOUISVILLE, CO 80027 |
| Telephone | 303-417-0500 |
| Fax | — |
| — | |
| Website | https://www.biodesix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biodesix Inc is a data-driven diagnostic solutions company. Its artificial intelligence-based platform helps to discover, develop, and commercialize solutions for clinical unmet needs, with a focus on lung disease. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. Additional info from NASDAQ: |
New Form ARS - BIODESIX INC <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-149700 <b>Size:</b> 980 KB
Read moreNew Form DEFA14A - BIODESIX INC <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-149694 <b>Size:</b> 566 KB
Read moreNew Form DEF 14A - BIODESIX INC <b>Filed:</b> 2026-04-09 <b>AccNo:</b> 0001193125-26-149633 <b>Size:</b> 3 MB
Read moreBiodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Read morePATIENCE JOHN 🟡 adjusted position in 0 shares (1 derivative) of BIODESIX INC (BDSX) Transaction Date: Mar 31, 2026 | Filing ID: 001495
Read moreBiodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
Read moreBiodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06728319 | A Multicenter, Retrospective, Chart Review Study Evaluating the Impact and Util… | — | Lung Nodules | Active_Not_Recruiting | 2024-09-19 | 2027-07-31 | ClinicalTrials.gov |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD… | — | NSCLC Stage IV | Terminated | 2021-02-01 | 2023-12-30 | ClinicalTrials.gov |
| NCT04100330 | A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or R… | Phase2 | Acute Myeloid Leukemia | Withdrawn | 2020-01-31 | 2020-03-27 | ClinicalTrials.gov |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immun… | — | Non-Small Cell Lung Cancer | Active_Not_Recruiting | 2016-04-04 | 2025-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Cytarabine | DRUG | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| Blood draw | PROCEDURE | Preclinical | Non Small Cell Lung Cancer | TERMINATED | NCT03951012 |
| placebo | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |
| Ficlatuzumab | BIOLOGICAL | Phase PHASE2 | Acute Myeloid Leukemia | WITHDRAWN | NCT04100330 |
| Docetaxel | DRUG | Phase PHASE3 | Carcinoma, Non-Small-Cell Lung | COMPLETED | NCT01652469 |
| Erlotinib | DRUG | Phase PHASE2 | Non-small Cell Lung Cancer | TERMINATED | NCT02318368 |